This post was originally published on this site Decades after establishing the recognized standard for performing and teaching clinical and personal breast exams, the MammaCare Foundation wants women and others to be aware that most breast cancers are found by hand. MammaCare’s goal is to train people what to feel for to identify suspicious breast…
This post was originally published on this site An experimental vaccine targeting the toxic form of tau protein reduced cellular tangles in the brain — a hallmark of Alzheimer’s — and eased behavioral and motor defects in a mouse model of the disease, a study showed. By generating high levels of anti-tau antibodies, this vaccine…
This post was originally published on this site Men who father children through assisted reproduction techniques, either in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), may be at a higher risk of developing prostate cancer, a study shows. Early screening for prostate cancer may also be beneficial for infertile men, according to the study,…
This post was originally published on this site Jazz Pharmaceuticals has enrolled the first participant in a Phase 2 trial assessing the efficacy of Defitelio (defibrotide) to prevent nerve cell toxicity in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are receiving chimeric antigen receptor (CAR) T-cell therapy. The multicenter open-label trial…
This post was originally published on this site Haichong Zhang, an assistant professor at Worcester Polytechnic Institute, has been given a Director’s Early Independence Award from the National Institutes of Health (NIH) to support his work in designing a robotic system to better detect and monitor prostate cancer. Currently, prostate cancer is diagnosed via a blood…
This post was originally published on this site Syros Pharmaceuticals‘ investigational oral inhibitor, SY-5609, can lead to a sustained inhibition of cancer growth in animal models of ovarian cancer and other solid tumors, preclinical data showed. The findings support the initiation of a Phase 1 trial testing the compound early next year, investigators said. Researchers…
This post was originally published on this site U.S. blood cancer specialists are aware of recent approvals for multiple myeloma patients and expect to increase their use of Darzalex (daratumumab) as first-line combination therapy, as well as Xpovio (selinexor) as a fifth-line combination therapy, according to a survey conducted by market research firm Spherix Global Insights. The…
This post was originally published on this site First-line treatment with a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) added to a shorter course of chemotherapy significantly extends the survival of people with advanced non-small cell lung cancer (NSCLC), compared to standard chemotherapy alone, early Phase 3 trial results show. The CheckMate-9LA trial (NCT03215706)…
This post was originally published on this site A Phase 3 trial exploring a combination of Seattle Genetics‘ tucatinib plus standard Kadcyla (ado-trastuzumab emtansine) in people with advanced HER2-positive breast cancer has dosed its first participant, the company announced. The trial — called HER2CLIMB-02 (NCT03975647) — is enrolling up to 460 adult patients with metastatic…
This post was originally published on this site T3D Therapeutics has secured the needed funding to move forward with its Phase 2 trial testing T3D-959 as a potential treatment for people with mild-to-moderate Alzheimer’s disease. The total funding includes $15 million from an investor, in addition to a $9 million award from the National Institute…
